Melanoma (primary nd
Contact us: [email protected]
Melanoma Tissue Array - 12 cases of normal epithelium, nevus, and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates. |
Z7020108 |
Biochain |
5 slides |
EUR 1657.2 |
Description: Our tissue products are produced by strictly following the IRB ethical standards and procedures and from highest quality tissues. Immediately after collection the tissues are placed in liquid nitrogen and examined by certified pathologists. The thickness of each individual section is ~5um. They are Hematoxylin and Eosin stained and quality tested by immunostaining with anti-beta-actin antibodies. Our tissue products are suitable for various studies on cellular level (RNA localization, Protein expression, etc.) on both normal and pathological cases. It is also an excellent control and educational tool. |
Human Primary Epidermal Melanocytes |
T4094 |
ABM |
5x10^5 cells / 1.0 ml |
Ask for price |
Human Primary Epidermal Melanocytes (hMela) |
cAP-0117 |
Angio Proteomie |
1Frozen Vial |
EUR 445.5 |
Melanoma Tissue Slide (Skin- Melanoma) |
12-801-10um |
ProSci |
10 um |
EUR 241.8 |
Melanoma Tissue Slide (Skin- Melanoma) |
12-801-4um |
ProSci |
4 um |
EUR 216.6 |
C32 (melanoma) |
ABC-TC0092 |
AcceGen |
1 vial |
Ask for price |
Description: Human amelanotic melanoma. C32 belongs to the C32r type cultures with the marker M2r substituting the original ring marker M2R. Tumours can be produced in nude mice after 1-2 months (1, 000, 000 cells injected). |
Malignant melanoma |
ME1004h |
TissueArray |
each |
EUR 306 |
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including pathology grade, TNM and clinical stage, 100 cases/100 cores, replacing ME1004g |
Malignant melanoma |
ME1006 |
TissueArray |
each |
EUR 378 |
Description: Malignant melanoma, metastatic malignant melanoma and nevus tissue array, including TNM and clinical stage (AJCC 8th edition), 100 cases/ 100 cores (core size 1.0mm),replacing ME1004h |
Human Melanoma CAFs |
CAF09 |
Neuromics |
1,000,000 cells |
EUR 1749.6 |
Melanoma tissue array |
ME483 |
TissueArray |
each |
EUR 270 |
Description: Melanoma tissue array, including TNM and clinical stage, 48 cases/48 cores, replaced by ME483a |
Melanoma (gp100) Protein |
20-abx263540 |
Abbexa |
-
Ask for price
-
Ask for price
-
Ask for price
|
|
|
Melanoma Antibody / PNL2 |
V3071-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma Antibody / PNL2 |
V3071SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: Anti-PNL2 is a novel melanoma marker monoclonal antibody, which has recently been introduced as an immunohistochemical reagent to stain melanocytes and tumors derived therefrom. The antigen recognized by PNL2 is different from Melan A and gp100. Its epitope is not destroyed by digestion with neuraminidase i.e. its epitope is not glycosylated. Anti-PNL2 may be most useful because of its high sensitivity for metastatic melanoma (87%), as opposed to 76% for anti-HMB45 and 82% for anti-MART-1. Anti-PNL2 labels intra-epidermal nevi while the dermal component of compound nevi are largely non-reactive with anti-PNL2. Antibodies against PNL2, MART-1 (Melan A) and HMB45 stain most clear cell sarcoma cells and a few cells in angiomyolipomas and lymphangioleiomyomatosis. Anti-PNL2 is a useful antibody for the identification of melanomas and clear cell sarcomas. Differential diagnosis is aided by the results from a panel of antibodies, including antibodies against HMB45, MART-1, tyrosinase, and MiTF. |
Melanoma (gp100), Antibody |
GWB-1D228F |
GenWay Biotech |
7 ml |
Ask for price |
|
Melanoma (gp100), Antibody |
GWB-ED7A36 |
GenWay Biotech |
1 ml |
Ask for price |
Melanoma, 48 cases (1.5mm) |
MEL961 |
Pantomics |
1 |
EUR 372 |
Description: Melanoma tissue array containing 12 cases of normal epithelium, nevus and carcinoma of the skin, and 36 cases of primary (26 cases) and metastatic (10 cases) melanomas in duplicates. |
Melanoma-associated, Antibody |
GWB-92DEFA |
GenWay Biotech |
1 ml |
Ask for price |
Melanoma (skin cancer) Exosome |
P141-MN |
101Bio |
- |
Ask for price |
GFP-HUVEC (Primary) |
P0027003 |
Addexbio |
One Frozen vial |
EUR 1066 |
Melanoma Marker(PNL2) Antibody |
BNCH0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCH0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Horseradish Peroxidase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCAP0894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), Alkaline Phosphatase conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC700894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF770 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC810894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680R conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC800894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC800894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF680 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC550894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF555 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC430894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF543 conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-100 |
Biotium |
100uL |
EUR 238.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNC050894-500 |
Biotium |
500uL |
EUR 652.8 |
Description: Primary antibody against Melanoma Marker(PNL2), CF405M conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCA0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), APC conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCP0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), PerCP conjugate, Concentration: 0.1mg/mL |
Melanoma Marker(PNL2) Antibody |
BNCR0894-250 |
Biotium |
250uL |
EUR 459.6 |
Description: Primary antibody against Melanoma Marker(PNL2), RPE conjugate, Concentration: 0.1mg/mL |
TnI (Primary) Antibody |
abx018056-100ug |
Abbexa |
100 ug |
EUR 410.4 |
|
TnI (Primary) Antibody |
abx018056-1mg |
Abbexa |
1 mg |
EUR 262.5 |
Melanoma Marker(PNL2), 1mg/mL |
BNUM0894-50 |
Biotium |
50uL |
EUR 396 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Melanoma Marker(PNL2), 0.2mg/mL |
BNUB0894-100 |
Biotium |
100uL |
EUR 225 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
Melanoma Marker(PNL2), 0.2mg/mL |
BNUB0894-500 |
Biotium |
500uL |
EUR 485 |
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
PMEL17 / Melanoma gp100 Antibody |
RQ4546 |
NSJ Bioreagents |
100ug |
EUR 356.15 |
|
Description: This gene is mapped to 12q13.2. It encodes a melanocyte-specific type I transmembrane glycoprotein. The encoded protein is enriched in melanosomes, which are the melanin-producing organelles in melanocytes, and plays an essential role in the structural organization of premelanosomes. This protein is involved in generating internal matrix fibers that define the transition from Stage I to Stage II melanosomes. This protein undergoes a complex pattern of prosttranslational processing and modification that is essential to the proper functioning of the protein. A secreted form of this protein that is released by proteolytic ectodomain shedding may be used as a melanoma-specific serum marker. Alternate splicing results in multiple transcript variants. |
Melanoma Membrane Tumor Lysate |
XBL-10750 |
ProSci |
0.1 mg |
EUR 1023 |
Description: Human melanoma tissue membrane protein lysate was prepared by isolating the membrane protein from whole tissue homogenates using a proprietary technique. The human melanoma tissue was frozen in liquid nitrogen immediately after excision and then stored at -70°C. The membrane protein is provided in a buffer including HEPES (pH 7.9), MgCl2, KCl, EDTA, Sucrose, Glycerol, sodium deoxycholate, NP-40, and a cocktail of protease inhibitors. For quality control purposes, the isolated melanoma tissue membrane protein pattern on SDS-PAGE gel is shown to be consistent for each lot by visualization with coomassie blue staining. The isolated melanoma tissue membrane protein is then Western analyzed by either GAPDH or β-actin antibody to confirm there is no signal or very weak signal. |
PMEL17 / Melanoma gp100 Antibody |
V9078-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078IHC-7ML |
NSJ Bioreagents |
7 ml |
EUR 424.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9078SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin. Metastatic amelanotic melanoma can often be confused with a variety of poorly differentiated carcinomas, large cell lymphomas, and sarcomas using H & E stains alone. It is also difficult to differentiate melanoma from spindle cell carcinomas and various types of mesenchymal neoplasms. It stains fetal and neonatal melanocytes, junctional and blue nevus cells, and malignant melanoma. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V9079-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V9079-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V9079SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: By immunohistochemistry, it specifically recognizes a protein in melanocytes and melanomas. This mAb reacts with junctional and blue nevus cells and variably with fetal and neonatal melanocytes. Intradermal nevi, normal adult melanocytes, and non-melanocytic cells are negative. It does not stain tumor cells of epithelial, lymphoid, glial, or mesenchymal origin.This Mab labels formalin-fixed, paraffin-embedded melanomas and other tumors showing melanocytic differentiation. |
PMEL17 / Melanoma gp100 Antibody |
V3916-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt] |
PMEL17 / Melanoma gp100 Antibody |
V3916-20UG |
NSJ Bioreagents |
20 ug |
EUR 186.15 |
|
Description: PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt] |
PMEL17 / Melanoma gp100 Antibody |
V3916SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 424.15 |
|
Description: PMEL17/Melanoma gp100/SILV plays a central role in the biogenesis of melanosomes. Involved in the maturation of melanosomes from stage I to II. The transition from stage I melanosomes to stage II melanosomes involves an elongation of the vesicle, and the appearance within of distinct fibrillar structures. Release of the soluble form, ME20-S, could protect tumor cells from antibody mediated immunity. [UniProt] |
PMEL17 / Melanoma gp100 Antibody |
V3929-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V3929-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V3929SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V3930-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V3930-20UG |
NSJ Bioreagents |
20 ug |
EUR 153.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
PMEL17 / Melanoma gp100 Antibody |
V3930SAF-100UG |
NSJ Bioreagents |
100 ug |
EUR 349.3 |
|
Description: Cytotoxic T lymphocytes (CTL's) recognize melanoma-associated antigens, which belong to three main groups. These groups include tumor-associated testis-specific antigens, melanocyte differentiation antigens and mutated or aberrantly expressed antigens, which are routinely used as markers to identify melanomas based on their binding to specific monoclonal antibodies. gp100, also designated ME20-M, ME20-S and PMEL 17, is classified as a melanocyte differentiation antigen and is expressed at low levels in normal cell lines and tissues, but is upregulated in melanocytes. gp100 is a highly glycosylated protein. It is also the product of proteolytic cleavage, which results in a secreted protein. The gp100 molecule is a 100kDa glycosylated protein that is cleaved into a small (26kDa) carboxy-terminal fragment and a larger amino- terminal section (60-64 kDa), which is subsequently cleaved to generate 26kDa and 34-38kDa fragments. |
Melanoma (primary nd